This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

8-10 June 2021
★ VIRTUAL EVENT

THE INDUSTRY’S EUROPEAN EVENT FOR ANTIBODY AND PROTEIN THERAPEUTIC SCIENCE, TECHNOLOGY AND NETWORKING

New for 2021! New Content! New Speakers!

6 NEW THEMED SESSION GROUPS FOR 2021!


  • COVID Antibody Treatment Successes, Failures and Models: What Have We Learned?
  • New Approaches to Multispecific Antibody Treatment
  • Advances in T-Cell Engaging Therapies


  • Antibody Screening, Discovery and Technology
  • Advances in Payloaded Antibodies
  • Exploiting and Understanding Avidity Engineering of Antibodies


Benefits of Virtual Format

  • Access a combination of pre-recorded & live case studies and new data presentations and view at your own pace with content available for 30 days
  • Engage with speakers during live Q&A and interactive surveys/polling. Plus, access on-demand content for viewing at your own pace
  • View exhibitors and technology showcases/scientific briefings & speak with live product specialists in our virtual exhibition
  • Access scientific posters and virtually meet (with video sharing) poster presenters who are showcasing their research in dedicated virtual poster rooms

AI-Enabled Virtual Networking

  • Connect with people from companies and topic interests most relevant to you. The AI based matchmaking will recommend top matches. You can see everyone registered for the event, but your most relevant matches are listed first. Utilize our built-in networking platform to browse the full attendee list and send private messages before, during and after the virtual event
  • Gain answers to your current antibody discovery and development challenges by scheduling 1-1 meetings with fellow attendees, speakers and exhibitors
  • Invite people into to your own private “room” to talk - where you can screenshare and share annotations to collaborate

About The Antibody Society

The Antibody Society is an international, non-profit representing individuals and organizations involved in antibody-related research and development. The Society has a variety of initiatives and working groups focused on improving the antibody field.

We are:

- Creating opportunities for education and networking;

- Monitoring and reporting advances in the commercial pipeline for antibody and CAR-T therapeutics;

- Creating standards for characterizing antibody and T-cell receptor repertoires, and engaging this field;

- Engaging government and international agencies on matters concerning the antibody community;

 Please join us!

DOWNLOAD WHITE PAPER

CAR-T and T-cell receptor (TCR) cell therapies are some of the most exciting emerging therapies on the market today, and their engineering strategies are crucial. This whitepaper discusses recent developments in CAR and TCR engineering and the overlap with antibody engineering, including:

  • Companies leading the way in TCR and T cell engineering
  • Novel platforms and enabling technologies
  • Technologies for Engineering CAR T cells
  • Technologies for Engineering TCRs (T cell receptors)
  • Lessons antibody engineers can learn from TCR and CAR T cell engineers

Paul W.H.I. Parren, Ph.D.

Board Member of the Antibody Society and Conference Committee Co-Chair

Leiden University Medical Center and Lava Therapeutics

“I feel honored to coordinate the scientific programming of the renowned Antibody Engineering and Therapeutics EUROPE conference on behalf of The Antibody Society. A team of stellar scientific advisors put together a program this year that is not-to-be-missed. I am therefore delighted that Informa Connect is digitizing this year’s event to allow it to move forward under these challenging circumstances.”